Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.48)
# 2,356
Out of 4,944 analysts
17
Total ratings
64.29%
Success rate
9.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $23.60 | +1,552.54% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.86 | +5,714.63% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $14.49 | +176.05% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $2.97 | +5,623.91% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $4.31 | +364.04% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $24.81 | +101.53% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $113.33 | +27.06% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $23.60
Upside: +1,552.54%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.86
Upside: +5,714.63%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $14.49
Upside: +176.05%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $2.97
Upside: +5,623.91%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $4.31
Upside: +364.04%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $24.81
Upside: +101.53%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $113.33
Upside: +27.06%